About HATIP

A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.

Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.

Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.

latest aidsmap news

• High rate of death amongst patients with HIV diagnosed late
• CD4 cell count increases sustained up to five years in developing-world treatment programmes
• Raltegravir may have role in PEP if exposure involves drug-resistant HIV
• Excellent outcomes from five years of antiretroviral use in Botswana
• Study explores verbal and non-verbal communication in unprotected sex between men
• IL-2 provides quick ‘AIDS rescue’, but effect does not always last
• Once-a-day etravirine should work as first-line treatment
• Second-line combinations fail twice as often as first-line ones in the first year
• If you can't switch, better to stay on failing treatment than stop it, studies show
• Non-nucleoside resistance is efficiently transmitted within infection ‘clusters’